PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Breast cancer vaccine shows promise in small clinical trial

Breast cancer vaccine shows promise in small clinical trial
2014-12-01
(Press-News.org) A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.

The study appears Dec. 1 in Clinical Cancer Research.

The new vaccine causes the body's immune system to home in on a protein called mammaglobin-A, found almost exclusively in breast tissue. The protein's role in healthy tissue is unclear, but breast tumors express it at abnormally high levels, past research has shown.

"Being able to target mammaglobin is exciting because it is expressed broadly in up to 80 percent of breast cancers, but not at meaningful levels in other tissues," said breast cancer surgeon and senior author William E. Gillanders, MD, professor of surgery. "In theory, this means we could treat a large number of breast cancer patients with potentially fewer side effects.

"It's also exciting to see this work progress from identifying the importance of mammaglobin-A, to designing a therapeutic agent, manufacturing it and giving it to patients, all by investigators at Washington University," he added.

The vaccine primes a type of white blood cell, part of the body's adaptive immune system, to seek out and destroy cells with the mammaglobin-A protein. In the smaller proportion of breast cancer patients whose tumors do not produce mammaglobin-A, this vaccine would not be effective.

In the new study, 14 patients with metastatic breast cancer that expressed mammaglobin-A were vaccinated. The Phase 1 trial was designed mainly to assess the vaccine's safety. According to the authors, patients experienced few side effects, reporting eight events classified as mild or moderate, including rash, tenderness at the vaccination site and mild flu-like symptoms. No severe or life-threatening side effects occurred.

Although the trial was designed to test vaccine safety, preliminary evidence indicated the vaccine slowed the cancer's progression, even in patients who tend to have less potent immune systems because of their advanced disease and exposure to chemotherapy.

"Despite the weakened immune systems in these patients, we did observe a biologic response to the vaccine while analyzing immune cells in their blood samples," said Gillanders, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University. "That's very encouraging. We also saw preliminary evidence of improved outcome, with modestly longer progression-free survival."

Of the 14 patients who received the vaccine, about half showed no progression of their cancer one year after receiving the vaccine. In a similar control group of 12 patients who were not vaccinated, about one-fifth showed no cancer progression at the one-year follow-up. Despite the small sample size, this difference is statistically significant.

Based on results of this study, Gillanders and his colleagues are planning a larger clinical trial to test the vaccine in newly diagnosed breast cancer patients, who, in theory, should have more robust immune systems than patients who already have undergone extensive cancer therapy.

"If we give the vaccine to patients at the beginning of treatment, the immune systems should not be compromised like in patients with metastatic disease," Gillanders said. "We also will be able to do more informative immune monitoring than we did in this preliminary trial. Now that we have good evidence that the vaccine is safe, we think testing it in newly diagnosed patients will give us a better idea of the effectiveness of the therapy."

INFORMATION:

This work was supported by the Breast Cancer Research Program (BCRP) of the Department of Defense Congressionally Directed Medical Research Programs (DOD/CDMRP), grant number W81XWH-61-0677; Gateway for Cancer Research, P-06-016; The Foundation for Barnes-Jewish Hospital; the National Cancer Institute (NCI) of the National Institutes of Health (NIH), T32 CA009621; the NCI Cancer Center Support Grant, P30 CA91842; and George and Diana Holway.

Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE. Safety and preliminary evidence of biological efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer. Clinical Cancer Research. Dec. 1, 2014.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

URL: https://news.wustl.edu/news/Pages/27732.aspx


[Attachments] See images for this press release:
Breast cancer vaccine shows promise in small clinical trial

ELSE PRESS RELEASES FROM THIS DATE:

Nearly 55 percent of US infants sleep with potentially unsafe bedding

Nearly 55 percent of US infants sleep with potentially unsafe bedding
2014-12-01
Nearly 55 percent of U.S. infants are placed to sleep with bedding that increases the risk of sudden infant death syndrome, or SIDS, despite recommendations against the practice, report researchers at the National Institutes of Health, the Centers for Disease Control and Prevention, and other institutions. Soft objects and loose bedding--such as thick blankets, quilts, and pillows--can obstruct an infant's airway and pose a suffocation risk, according to the NIH's Safe to Sleep campaign. Soft bedding has also been shown to increase the risk of SIDS Infants should be ...

Political correctness in diverse workplace fosters creativity

Political correctness in diverse workplace fosters creativity
2014-12-01
UNIVERSITY OF CALIFORNIA, BERKELEY'S HAAS SCHOOL OF BUSINESS -People may associate political correctness with conformity but new research finds it also correlates with creativity in work settings. Imposing a norm that sets clear expectations of how women and men should interact with each other into a work environment unexpectedly encourages creativity among mixed-sex work groups by reducing uncertainty in relationships. The study highlights a paradoxical consequence of the political correctness (PC) norm. While PC behavior is generally thought to threaten the free expression ...

Behavioral interventions to prevent progression to diabetes equally effective in men and women

2014-11-28
Behavioural and drug interventions aiming to prevent people with prediabetes progressing to full blown type 2 diabetes are equally effective for both sexes at preventing progression and reducing weight, according to a new systematic review and meta-analysis. The research is by Dr Anna Glechner, Danube University Krems, Austria, and Dr Jürgen Harreiter, Medical University of Vienna, Austria, and colleagues. Prediabetes is a general term that refers to an intermediate stage between normal blood glucose control (normoglycaemia) and type 2 diabetes (high blood glucose ...

Long-term complication rate low in nose job using patient's own rib cartilage

2014-11-27
Using a patient's own rib cartilage (autologous) for rhinoplasty appears to be associated with low rates of overall long-term complications and problems at the rib site where the cartilage is removed, according to a report published online by JAMA Facial Plastic Surgery. Autologous rib cartilage is the preferred source of graft material for rhinoplasty because of its strength and ample volume. However, using rib cartilage for dorsal augmentation to build up the bridge of the nose has been criticized for its tendency to warp and issues at the cartilage donor site, such ...

Survival differences seen for advanced-stage laryngeal cancer

2014-11-27
The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal of the voice box), to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery. The larynx is a common site of head and neck cancer with more than 10,000 cases annually. Over the past two decades, treatment for advanced-stage laryngeal cancer has shifted ...

Secret of tetanus toxicity offers new way to treat motor neuron disease

2014-11-27
The way that tetanus neurotoxin enters nerve cells has been discovered by UCL scientists, who showed that this process can be blocked, offering a potential therapeutic intervention for tetanus. This newly-discovered pathway could be exploited to deliver therapies to the nervous system, opening up a whole new way to treat neurological disorders such as motor neuron disease and peripheral neuropathies. The research in mice, published in Science and funded by the Medical Research Council, shows that proteins called nidogens that coat cell surfaces are key to tetanus neurotoxin ...

Using social media for behavioral studies is cheap, fast, but fraught with biases

2014-11-27
PITTSBURGH--The rise of social media has seemed like a bonanza for behavioral scientists, who have eagerly tapped the social nets to quickly and cheaply gather huge amounts of data about what people are thinking and doing. But computer scientists at Carnegie Mellon University and McGill University warn that those massive datasets may be misleading. In a perspective article published in the Nov. 28 issue of the journal Science, Carnegie Mellon's Juergen Pfeffer and McGill's Derek Ruths contend that scientists need to find ways of correcting for the biases inherent in the ...

A numbers game: Math helps to predict how the body fights disease

A numbers game: Math helps to predict how the body fights disease
2014-11-27
Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease. The finding, published today in the journal Science, has implications for our understanding of how harmful or beneficial immune responses can be manipulated for better health. The research team used mathematics and computer modeling to understand how complex signaling impacts the size of the response by key infection-fighting immune cells called ...

Education is key to climate adaptation

2014-11-27
Given that some climate change is already unavoidable--as just confirmed by the new IPCC report--investing in empowerment through universal education should be an essential element in climate change adaptation efforts, which so far focus mostly in engineering projects, according to a new study from the International Institute for Applied Systems Analysis (IIASA) published in the journal Science. The article draws upon extensive analysis of natural disaster data for 167 countries over the past four decades as well as a number of studies carried out in individual countries ...

Notre Dame biologist leads sequencing of the genomes of malaria-carrying mosquitoes

2014-11-27
Nora Besansky, O'Hara Professor of Biological Sciences at the University of Notre Dame and a member of the University's Eck Institute for Global Health, has led an international team of scientists in sequencing the genomes of 16 Anopheles mosquito species from around the world. Anopheles mosquitoes are responsible for transmitting human malaria parasites that cause an estimated 200 million cases and more than 600 thousand deaths each year. However, of the almost 500 different Anopheles species, only a few dozen can carry the parasite and only a handful of species are responsible ...

LAST 30 PRESS RELEASES:

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments

Using smartphones to improve disaster search and rescue

Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing

Ultrafast material captures toxic PFAS at record speed and capacity

Plant phenolic acids supercharge old antibiotics against multidrug resistant E. coli

UNC-Chapel Hill study shows AI can dramatically speed up digitizing natural history collections

OYE Therapeutics closes $5M convertible note round, advancing toward clinical development

Membrane ‘neighborhood’ helps transporter protein regulate cell signaling

Naval aviator turned NPS doctoral student earns national recognition for applied quantum research

[Press-News.org] Breast cancer vaccine shows promise in small clinical trial